ROCHESTER GENERAL HOSPITAL

Rochester General Hospital conducts the first U.S. clinical trial for Aqua Pass, a non-invasive suit using warm air to remove fluid through the skin, aiming to reduce hospitalizations for heart failure patients.

Rochester General Hospital (RGH) is the first U.S. site for a pivotal clinical trial of the AquaPass, a non-invasive system designed to help congestive heart failure and end-stage renal disease patients with fluid overload. The trial, led by Dr. Scott Feitell, aims to offer a renal-independent, drug-free solution using warm air to evaporate fluid through the skin. Preliminary results from Israel showed significant weight reduction and improved quality of life, with no hospital readmissions during testing.

FIRE1 completed patient enrollment in the U.S. Early Feasibility Study for its FIRE1™ System, aimed at remote heart failure monitoring by measuring the inferior vena cava. The study involved 15 patients across five U.S. centers. The system seeks to improve heart failure management by enabling patients to monitor fluid volume at home, potentially reducing hospital admissions.